Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sangamo Therapeutics (NASDAQ: SGMO) has made significant strides in its clinical pipeline, including advancements in its Phase 1/2 STAAR study for Fabry disease, where 20 patients have been dosed. The company has also initiated the dosing of a third patient in the TX200 CAR-Treg study for kidney transplantation, with regulatory feedback supporting dose escalation. Additionally, Sangamo has prioritized its neurology pipeline by introducing the Nav1.7 target for chronic neuropathic pain, expecting IND submission in 2024. However, a corporate restructuring will reduce the workforce by 27%, aiming for annual cost savings of approximately $31 million. Preliminary Q1 2023 revenue is projected at $158 million, a sharp rise from $28.2 million in Q1 2022, mainly due to collaboration agreements with Biogen. Total operating expenses are anticipated to range from $120 million to $140 million, reflecting impairment charges related to recent collaborations.
Sangamo Therapeutics, a genomic medicine company, is set to release its first quarter 2023 financial results after market close on April 26, 2023. A conference call will follow on April 27, 2023 at 8:30 a.m. ET, open to the public for financial and business updates.
Participants can register for the call via a provided link, with options to dial in or use a direct phone connect. A replay will be accessible post-call under the company's 'Events and Presentations' section.
Sangamo is focused on innovative genomic medicines, leveraging proprietary technologies to address unmet medical needs. For more information, visit their website.
Sangamo Therapeutics (SGMO) recently announced its fourth quarter and full year 2022 financial results, reporting a consolidated net loss of $52.0 million for Q4 and $192.3 million for the year. Revenues for Q4 were $27.2 million, a slight decrease from $28.0 million in 2021, while total revenues for 2022 increased to $111.3 million from $110.7 million. Key updates include promising data from the Fabry disease study, with 78% Gb3 substrate clearance at 6 months, and plans for a Phase 3 trial expected by late 2023. The company aims to optimize resources toward Fabry, CAR-Treg, and CNS programs in 2023.